$VNRX

VolitionRx Limited (VNRX) reported its Q4 2025 earnings, highlighting significant revenue growth driven by successful product launches. The company anticipates continued upward momentum in 2026, supported by expanding market demand for its diagnostic products. Management provided positive guidance for future quarters, indicating a robust pipeline and strategic partnerships. However, heightened operating expenses were noted, raising concerns about profitability in the short term. Overall, the earnings call conveyed a bullish outlook balanced with caution regarding cost management.